Gordon D Wilkie

US Patent:

20120029213, Feb 2, 2012

Filed:

Jun 29, 2011

Appl. No.:

13/171971

Inventors:

Brian Austad - Tewksbury MA, US
Farid Benayoud - North Andover MA, US
Trevor Calkins - Stoughton WI, US
Silvio Campagna - Candia NH, US
Charles E. Chase - Londonderry NH, US
William Christ - Andover MA, US
Francis G. Fang - Andover MA, US
Yongbo Hu - Westborough MA, US
Bryan M. Lewis - North Brunswick NJ, US
Marc Pesant - Saint-Colomban, CA
Matthew Schnaderbeck - Methuen MA, US
Gordon Wilkie - North Andover MA, US
Xiaojie Zhu - Andover MA, US

Assignee:

Eisai R&D Management Co., Ltd. - Tokyo

International Classification:

C07D 407/14
C07D 493/20
C07D 493/10
C07F 7/08
C07D 307/28

US Classification:

549214, 549348, 549501, 549337

Abstract:

Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.

US Patent:

20110172427, Jul 14, 2011

Filed:

Aug 26, 2009

Appl. No.:

13/060979

Inventors:

Taiju Nakamura - Kamisu, JP
Masaaki Matsuda - Tsukuba, JP
Yongbo Hu - Chestnut Hill MA, US
Daiju Hasegawa - Tsukuba, JP
Yorihisa Hoshino - Tsukuba, JP
Kazato Inanaga - Kamisu, JP
Minetaka Isomura - Kamisu, JP
Nobuaki Sato - Tsukuba, JP
Kazuhiro Yoshizawa - Kamisu, JP
George A. Moniz - Cambridge MA, US
Gordon D. Wilkie - North Andover MA, US
Francis G. Fang - Andover MA, US
Yoshihiro Nishikawa - Kamisu, JP

Assignee:

EISAI R&D MANAGEMENT CO., LTD. - Tokyo

International Classification:

C07D 471/04
C07C 257/06
C07D 401/14
C07D 401/04

US Classification:

546119, 558 6, 546194, 5462741

Abstract:

This invention relates to a new synthesis, intermediates and precursors leading to a mixture of the compounds 11 and 12 as shown below. It also relates to the resolution of the stereoisomeric mixture to provide in substantial stereochemical purity compound 12. The synthesis of the invention involves preparation of compound 7 and compound 10 as shown below and their reaction to prepare a mixture of compound 11 and compound 12.

US Patent:

20220281879, Sep 8, 2022

Filed:

Aug 12, 2020

Appl. No.:

17/633440

Inventors:

- Cambridge MA, US
Debra Mazaik - Cambridge MA, US
Gordon Wilkie - Cambridge MA, US
Joshua D. Waetzig - Cambridge MA, US
Brian Heinrich - Cambridge MA, US
Lauren MacEachern - Dartmouth, CA
Dominik Siegel - Dottikon, CH
Harald Ohmer - Dottikon, CH
Steven C. Johnston - Woburn MA, US

International Classification:

C07D 487/04

Abstract:

Various salt forms of Compound (I) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1.5 Compound (I) succinate, 1:1 Compound (I) hydrochloride salt, and 1:1 Compound (I) fumarate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating or ameliorating fibrodysplasia ossificans progressive in a subject.

US Patent:

20210147433, May 20, 2021

Filed:

Jan 20, 2021

Appl. No.:

17/153727

Inventors:

- Cambridge MA, US
Brenton Mar - Cambridge MA, US
Brian Heinrich - Cambridge MA, US
Gordon Wilkie - Cambridge MA, US
Lauren MacEachern - Dartmouth, CA

International Classification:

C07D 487/04
A61P 35/00
A61P 17/00

Abstract:

Crystalline Forms of Compound (I):pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.